Next Article in Journal
Update in Systemic and Targeted Therapies in Gastrointestinal Oncology
Next Article in Special Issue
Progress in Adenoviral Capsid-Display Vaccines
Previous Article in Journal
Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets
Previous Article in Special Issue
The Repertoire of Adenovirus in Human Disease: The Innocuous to the Deadly

Oncolytic Adenoviruses in Gastrointestinal Cancers

Department of Medicine, Division of Hematology Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85205, USA
Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
Center for Individualized Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
Mayo Clinic Cancer Center, 5881 E Mayo Blvd, Phoenix, AZ 85054, USA
Author to whom correspondence should be addressed.
Biomedicines 2018, 6(1), 33;
Received: 31 January 2018 / Revised: 5 March 2018 / Accepted: 9 March 2018 / Published: 11 March 2018
(This article belongs to the Special Issue Adenoviruses: From Virus to Medicine)
Gastrointestinal malignancies are challenging cancers with considerable economic and societal impacts on health care systems worldwide. While advances in surgical approaches have provided benefits to a proportion of patients, only modest improvements have been attained in the treatment of patients with advanced disease, resulting in limited improvement in survival rates in these patients. Oncolytic adenoviruses are being developed to address gastrointestinal malignancies. Each platform has evolved to maximize tumor-cell killing potency while minimizing toxicities. Tumor-specific bioengineered adenoviruses using chimeric promoters, prodrug convertase enzymes, lethal genes, tumor suppressor genes, and pseudo-typed capsids can provide the innovations for eventual success of oncolytic virotherapy. This article will review the developments in adenoviral platforms in the context of specific gastrointestinal cancers. From the bench to the implementation of clinical trials, this review aims to highlight advances in the field from its early days to the current state of affairs as it pertains to the application of adenoviral oncolytic therapy to gastrointestinal cancers. View Full-Text
Keywords: adenovirus; oncovirotherapy; assessment of adeno-vector safety; gastrointestinal cancers; oncolytic therapy adenovirus; oncovirotherapy; assessment of adeno-vector safety; gastrointestinal cancers; oncolytic therapy
Show Figures

Graphical abstract

MDPI and ACS Style

Yokoda, R.T.; Nagalo, B.M.; Borad, M.J. Oncolytic Adenoviruses in Gastrointestinal Cancers. Biomedicines 2018, 6, 33.

AMA Style

Yokoda RT, Nagalo BM, Borad MJ. Oncolytic Adenoviruses in Gastrointestinal Cancers. Biomedicines. 2018; 6(1):33.

Chicago/Turabian Style

Yokoda, Raquel T., Bolni M. Nagalo, and Mitesh J. Borad. 2018. "Oncolytic Adenoviruses in Gastrointestinal Cancers" Biomedicines 6, no. 1: 33.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop